Literature DB >> 8279156

Controversies in patient selection for liver transplantation.

E B Keeffe1, C O Esquivel.   

Abstract

A variety of specific conditions often stimulate controversy regarding candidacy for liver transplantation. We review the published experience with liver transplantation for alcoholic liver disease, fulminant and chronic hepatitis B, and hepatocellular carcinoma and transplantation in older subjects. Liver transplantation for alcoholic liver disease and in subjects older than 60 years is becoming less controversial because recent data demonstrate that these patients have excellent survival and good quality of life after transplantation. Only 10% to 15% of persons with alcoholism return to drinking after transplantation, and most do so only transiently. Liver transplantation for patients with hepatitis B virus infection or primary liver cancer is more problematic because recurrent disease is common in both conditions. After transplantation for chronic hepatitis B, 80% to 90% of patients have reinfection of the allograft and long-term survival is 45% to 50%. Patients receiving transplants for hepatocellular carcinoma have only 20% to 30% long-term survival, but these survivors are cured of malignancy. Data are presented to support continued liver transplantation for chronic hepatitis B and hepatocellular carcinoma; however, patients must be selected based on factors that predict a favorable outcome, and experimental therapies should be employed to explore ways to improve the existing survival rates.

Entities:  

Keywords:  Professional Patient Relationship

Mesh:

Year:  1993        PMID: 8279156      PMCID: PMC1022349     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  43 in total

1.  Liver transplantation for patients with hepatitis B: what have we learned from our results?

Authors:  J R Lake; T L Wright
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

2.  Alcoholics and liver transplantation. The Ethics and Social Impact Committee of the Transplant and Health Policy Center.

Authors:  C Cohen; M Benjamin
Journal:  JAMA       Date:  1991-03-13       Impact factor: 56.272

3.  Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients.

Authors:  D Samuel; A Bismuth; D Mathieu; J L Arulnaden; M Reynes; J P Benhamou; C Brechot; H Bismuth
Journal:  Lancet       Date:  1991-04-06       Impact factor: 79.321

4.  Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease.

Authors:  S Todo; A J Demetris; D Van Thiel; L Teperman; J J Fung; T E Starzl
Journal:  Hepatology       Date:  1991-04       Impact factor: 17.425

5.  Patterns of hepatitis delta virus reinfection and disease in liver transplantation.

Authors:  A Ottobrelli; A Marzano; A Smedile; S Recchia; M Salizzoni; C Cornu; M E Lamy; J B Otte; B De Hemptinne; A Geubel
Journal:  Gastroenterology       Date:  1991-12       Impact factor: 22.682

6.  Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation.

Authors:  I Yokoyama; B Carr; H Saitsu; S Iwatsuki; T E Starzl
Journal:  Cancer       Date:  1991-11-15       Impact factor: 6.860

7.  Hepatic resection versus transplantation for hepatocellular carcinoma.

Authors:  S Iwatsuki; T E Starzl; D G Sheahan; I Yokoyama; A J Demetris; S Todo; A G Tzakis; D H Van Thiel; B Carr; R Selby
Journal:  Ann Surg       Date:  1991-09       Impact factor: 12.969

8.  Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients.

Authors:  B Ringe; R Pichlmayr; C Wittekind; G Tusch
Journal:  World J Surg       Date:  1991 Mar-Apr       Impact factor: 3.352

9.  Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications.

Authors:  J G O'Grady; H M Smith; S E Davies; H M Daniels; P T Donaldson; K C Tan; B Portmann; G J Alexander; R Williams
Journal:  J Hepatol       Date:  1992-01       Impact factor: 25.083

10.  Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization.

Authors:  R Müller; G Gubernatis; M Farle; G Niehoff; H Klein; C Wittekind; G Tusch; H U Lautz; K Böker; W Stangel
Journal:  J Hepatol       Date:  1991-07       Impact factor: 25.083

View more
  1 in total

1.  A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C.

Authors:  M S Bayliss; B Gandek; K M Bungay; D Sugano; M A Hsu; J E Ware
Journal:  Qual Life Res       Date:  1998-01       Impact factor: 4.147

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.